== To measure the ability of the vaccine candidates to activate CTLs, CD8+T cells from lymph nodes of the mice were isolated by magnetic cell sorting and incubated with irradiated dendritic cells (DCs) pulsed with the immunizing peptides on ELISPOT plates
== To measure the ability of the vaccine candidates to activate CTLs, CD8+T cells from lymph nodes of the mice were isolated by magnetic cell sorting and incubated with irradiated dendritic cells (DCs) pulsed with the immunizing peptides on ELISPOT plates. gave CTLs which recognized only nonglycosylated peptide. Antibodies elicited by the glycosylated tripartite vaccine were significantly more lytic compared with the unglycosylated control. As a result, immunization with the glycosylated tripartite vaccine was superior in tumor Bacitracin prevention. Besides its own aptness as a clinical target, these studies of MUC1 are likely predictive of a covalent linking strategy applicable to many additional tumor-associated antigens. Keywords:cancer vaccine, multicomponent, chemical synthesis, Tn antigen A large number of carcinomas of breast, ovary, colon, rectum, pancreas, and prostate exhibit a striking overexpression of MUC1 resulting in a loss of polarization and altered glycosylation (1,2). MUC1 is a heavily glycosylated type 1 transmembrane mucin that is expressed on the apical surface of glandular epithelial cells at low levels and at very high levels following transformation. Human MUC1 is composed of a cytoplasmic signaling peptide, a transmembrane domain, and an ectodomain composed of a variable number tandem repeats of twenty amino acids. Each repeat contains five potentialO-glycosylation sites. The glycosylation pattern depends on the tissue of origin and the physiological state of the tissue (1,3). Tumor-associated MUC1 is aberrantly glycosylated due to a lack of core 1,3-galactosyltransferase (T-synthase) (4), producing truncated carbohydrate structures such as Tn (GalNAc-Thr), STn (Neu5Ac-(2,6)-GalNAc-Thr), and ThomsenFriedenreich (TF) antigen (Gal-(1,3)-GalNAc-Thr). Recently, the NCI Translational Research Working Group prioritized cancer vaccine targets based on therapeutic function, immunogenicity, role of Ag in oncogenicity, specificity, expression level, stem cell expression, percentage of patients with antigen positive cancer, and cellular location (5). MUC1 was ranked second of 75 tumor-associated antigens. In this respect, MUC1 displays nearly ubiquitous expression in a wide variety of tumor Bacitracin types: It is found on cancer stem cells and has a functional role in tumorigenesis. Humoral responses to MUC1 have been observed in benign diseases and carcinoma patients and the presence of circulating antibodies against MUC1 at the time of cancer diagnosis has been correlated with a favorable disease outcome in breast cancer patients (6,7). The MUC1-derived peptide sequences RPAPGS, PPAHGVT, and PDTRP have been identified as the most frequent minimal epitopes (8,9). Furthermore, modification of the peptides with GalNAc (Tn-antigen) led to stronger antibody binding. It has been proposed that the improved binding is due to saccharide induced conformational change Bacitracin of the peptide backbone (1012). Cytotoxic T lymphocytes (CTLs) isolated from patients Rabbit polyclonal to ZNF624.Zinc-finger proteins contain DNA-binding domains and have a wide variety of functions, mostof which encompass some form of transcriptional activation or repression. The majority ofzinc-finger proteins contain a Krppel-type DNA binding domain and a KRAB domain, which isthought to interact with KAP1, thereby recruiting histone modifying proteins. Zinc finger protein624 (ZNF624) is a 739 amino acid member of the Krppel C2H2-type zinc-finger protein family.Localized to the nucleus, ZNF624 contains 21 C2H2-type zinc fingers through which it is thought tobe involved in DNA-binding and transcriptional regulation with breast carcinoma can recognize epitopes present on MUC1 tandem repeat peptide (13). It has been proposed that T cell epitopes from the MUC1 core domain are packaged within tumor cells in their truncated glycosylation state into major histocompatibility complex (MHC) class I molecules, leading to natural MHC-restricted recognition of hypoglycosylated epitopes (1417). Several MUC1-derived HLA-A2-binding peptides have been identified including STAPPAHGV and SAPDTRPAPG (13,18,19). Early efforts to develop MUC1-based cancer vaccines focused on the use of unglycosylated MUC1 tandem repeat peptides of different lengths, conjugated to different carriers and/or administered with an adjuvant (8,2027). In general, these strategies have failed to elicit effective immune responses to MUC1-expressing cancer cells, probably due to the conformational disparities between nonglycosylated vaccine sequences and tumor-expressed, aberrantly glycosylated MUC1 (1012). The immunogenicity of carbohydrate epitopes (Tn- or sialosyl-Tn) conjugated to an antigenically irrelevant carrier protein has been examined in mice, however, these constructs elicited only modest IgM and IgG antibody responses (2831). Such vaccine candidates suffer from immune suppression by the carrier protein and, in addition, cannot activate CTL responses. A synthetic 60-mer MUC1 tandem-repeat peptide, which was glycosylated by polypeptide GalNAc transferases to give saturatingO-glycan occupancy (five sites per repeat), elicited only modest antibody responses (32). Recent clarifying studies have shown that a densely glycosylated MUC1 glycopeptide cannot be processed by antigen-presenting cells (APCs) (17), thereby compromising the presentation of class I and class II glycopeptides; consequently, Thelpercells and CTLs will not be activated. Interestingly, glycopeptides carrying the Tn- Bacitracin or TF-antigens have been used to induce a carbohydrate-specific cytotoxic T cell response in mice (33)..